W. Jeske

发表

Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices.

W. Jeske, J. Walenga, B. Menapace, 2016, Biomarkers in medicine.

Left Ventricular Assist Device–Induced Coagulation and Platelet Activation and Effect of the Current Anticoagulant Therapy Regimen

A. Heroux, W. Jeske, J. Walenga, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices

J. Newman, W. Jeske, J. Walenga, 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Interactions of Oversulfated Chondroitin Sulfate (OSCS) From Different Sources With Unfractionated Heparin

D. Hoppensteadt, J. Fareed, E. Litinas, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

An overview of hemostasis and thrombosis

D. Hoppensteadt, W. Jeske, J. Walenga, 2007 .

ABO blood group and procoagulant factors: the hypercoagulation hypothesis ABO and Procoagulant Factors

W. Jeske, O. Habeeb, J. Muraskas, 2019, Pediatric Research.

US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins

G. Montalescot, J. Nicolau, J. Fareed, 2012, Journal of Thrombosis and Thrombolysis.

Effect of SR 121566 A , a Potent GP IIb-IIIa Antagonist , on the HIT Serum / heparin-Induced Platelet Mediated Activation of Human Endothelial Cells

J. Herbert, P. Savi, W. Jeske, 2018 .

Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia.

W. Jeske, J. Walenga, M. Prechel, 2010, Thrombosis research.

Laboratory methods and management of patients with heparin-induced thrombocytopenia.

W. Jeske, J. Walenga, M. Prechel, 2010, Methods in molecular biology.

Mechanisms of Venous and Arterial Thrombosis in Heparin-Induced Thrombocytopenia

H. Messmore, W. Jeske, J. Walenga, 2000, Journal of Thrombosis and Thrombolysis.

Laboratory methods for heparin-induced thrombocytopenia.

W. Jeske, J. Walenga, M. Prechel, 2004, Methods in molecular medicine.

Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications--a review.

F. Fabris, J. Fareed, W. Jeske, 2000, Archives of pathology & laboratory medicine.

Pathophysiology of Heparin-Induced Thrombocytopenia

F. Fabris, J. Fareed, Sarfraz Ahmad, 2000 .

Synthetic Pentasaccharides Do Not Cause Platelet Activation by Antiheparin-Platelet Factor 4 Antibodies

J. Herbert, D. Hoppensteadt, J. Fareed, 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Laboratory Diagnosis of Heparin-Induced Thrombocytopenia

W. Jeske, J. Walenga, M. Bakhos, 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets.

J. Herbert, W. Jeske, J. Walenga, 1997, Thrombosis research.

Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?

D. Hoppensteadt, J. Fareed, C. Adiguzel, 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Platelet production, structure, and function

W. Jeske, 2020 .

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa

D. Hoppensteadt, J. Fareed, E. Ramacciotti, 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Reversal of new oral anticoagulants and personalized medicine.

J. Fareed, O. Iqbal, W. Jeske, 2017, Personalized medicine.

Reversal of Target-Specific Oral Anticoagulants

W. Jeske, 2016 .

Pharmacology of argatroban

D. Hoppensteadt, J. Fareed, W. Jeske, 2010, Expert review of hematology.

The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary).

E. Peterson, F. Edwards, D. Shahian, 2005, The Annals of thoracic surgery.

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.

M. Samama, J. Fareed, W. Jeske, 1997, Thrombosis research.

The Effect of a Novel Glycoprotein IIb/IIIa Antagonist, SR 121566A, on Platelet Aggregation and Activation in Rhesus Monkeys

J. Herbert, D. Hoppensteadt, J. Fareed, 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

D. Hoppensteadt, J. Fareed, O. Iqbal, 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Qualitative disorders of platelets and vasculature

W. Jeske, P. Dechristopher, 2020 .

Inflammatory cytokines in robot-assisted thoracic surgery versus video-assisted thoracic surgery

W. Vigneswaran, Z. Abdelsattar, W. Jeske, 2021, Journal of thoracic disease.

Thrombocytopenia and thrombocytosis

W. Jeske, P. Dechristopher, 2020, Rodak's Hematology.

Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.

Jason E. Moore, Deepak L. Bhatt, T. Grosser, 2017, Journal of the American College of Cardiology.

Statin Drugs and Dietary Isoprenoids Downregulate Protein Prenylation in Signal Transduction and Are Antithrombotic and Prothrombolytic Agents

G. Shen, J. Fenton, W. Jeske, 2004, Biochemistry (Moscow).

Troponin I levels in patients with preeclampsia.

R. Mestril, D. Arab, W. Jeske, 2007, The American journal of medicine.

Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.

J. Fareed, W. Jeske, J. Walenga, 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Section Review—Cardiovascular & Renal: Recent Developments in Antithrombotic Agents

D. Hoppensteadt, J. Fareed, W. Jeske, 1995 .

Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin

D. Hoppensteadt, J. Fareed, Q. Ma, 2003, Clinical pharmacokinetics.

armful Effects of Aspirin in the Perioperative etting oes Preoperative Aspirin Cause Increased ostoperative Blood Loss ?

E. Peterson, F. Edwards, C. Bridges, 2005 .

Low molecular weight heparins: are they different?

D. Hoppensteadt, J. Fareed, W. Jeske, 1998, The Canadian journal of cardiology.

Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.

D. Hoppensteadt, J. Fareed, Sarfraz Ahmad, 2002, Thrombosis research.

Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist.

S. Mousa, J. Fareed, W. Jeske, 2010, Methods in molecular biology.

Antiplatelet Therapy Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist

S. Mousa, J. Fareed, W. Jeske, 2010, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin‐induced thrombocytopenia

D. Hoppensteadt, O. Iqbal, H. Messmore, 2008, British journal of haematology.

Update on the clinical applications of argatroban.

D. Hoppensteadt, J. Fareed, W. Jeske, 2006, Future cardiology.

Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia

W. Jeske, J. Walenga, M. Bakhos, 2005, Current opinion in pulmonary medicine.

Affinity purification of heparin‐dependent antibodies to platelet factor 4 developed in heparin‐induced thrombocytopenia: biological characteristics and effects on platelet activation

Y. Gruel, J. Amiral, W. Jeske, 2000, British journal of haematology.

Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG.

D. Hoppensteadt, J. Fareed, Sarfraz Ahmad, 2002, Thrombosis research.

Compositional Differences in Commercially Available Prothrombin Complex Concentrates

J. Fareed, J. Harenberg, W. Jeske, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Blood Coagulation and Anticoagulant Drugs

J. Fareed, W. Jeske, J. Walenga, 2003 .

The relationship between reticulated platelets, intestinal alkaline phosphatase, and necrotizing enterocolitis.

A. Maheshwari, W. Jeske, O. Habeeb, 2014, Journal of pediatric surgery.

Tissue Factor-Mediated Activation of the Prothrombin Complex Concentrate (PCC) is Differently Inhibited by Dabigatran, Rivaroxaban, and Apixaban

D. Hoppensteadt, J. Fareed, W. Jeske, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Biochemical and Pharmacologic Rationale for Synthetic Heparin Polysaccharides

J. Fareed, W. Jeske, J. Walenga, 2005 .

Pharmacologic profile of certoparin.

J. Fareed, W. Jeske, H. Wolf, 1999, Expert opinion on investigational drugs.

A survey of venous thrombosis models.

J. Fareed, O. Iqbal, W. Jeske, 2004, Methods in molecular medicine.

Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate

J. Bates, J. Dordick, Fuming Zhang, 2022, Pharmaceuticals.

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

R. Linhardt, D. Hoppensteadt, J. Fareed, 2007, Thrombosis research.

Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent

M. Samama, J. Fareed, W. Jeske, 2002, Expert opinion on investigational drugs.

Short- and long-acting synthetic pentasaccharides as antithrombotic agents

J. Fareed, W. Jeske, J. Walenga, 2005, Expert opinion on investigational drugs.

Chemometric analysis of porcine, bovine and ovine heparins

Zhenqing Zhang, R. Linhardt, Fuming Zhang, 2019, Journal of pharmaceutical and biomedical analysis.

Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin

D. Hoppensteadt, J. Fareed, W. Jeske, 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin

R. Linhardt, D. Hoppensteadt, J. Fareed, 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins

R. Linhardt, J. Dordick, Fuming Zhang, 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Comparative Studies on Branded Enoxaparin and a US Generic Version of Enoxaparin

J. Cunanan, D. Hoppensteadt, J. Fareed, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Isolation and Characterization of Heparin From Tuna Skins

D. Hoppensteadt, C. Dietrich, W. Jeske, 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Statin drugs and dietary isoprenoids as antithrombotic agents.

G. Shen, F. Ofosu, J. Fenton, 2000, Hematology/oncology clinics of North America.

Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components

J. Fareed, W. Jeske, Fakiha Siddiqui, 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression.

R. Altman, J. Fareed, W. Jeske, 2000, Thrombosis research.

Comparative Anticoagulant and Platelet Modulatory Effects of Enoxaparin and Sulodexide

J. Cunanan, D. Hoppensteadt, J. Fareed, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

D. Hoppensteadt, J. Fareed, E. Ramacciotti, 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.

W. Jeske, J. Walenga, M. Bakhos, 2004, Seminars in thrombosis and hemostasis.

Urinary Prothrombin Fragment 1 + 2 as an Endogenous Marker of Venous Thromboembolism

J. Fareed, W. Jeske, O. Dahl, 2019 .

Soluble Adhesion Molecules in the HIT Syndrome: Pathophysiologic Role and Therapeutic Modulation

D. Hoppensteadt, J. Fareed, R. McKenna, 1999, Clinical and applied thrombosis/hemostasis.

Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.

J. Fareed, Q. Ma, W. Jeske, 2001, Thrombosis research.

Efficacy of pentasaccharide in a dog model of hemodialysis.

T. Ing, J. Herbert, D. Hoppensteadt, 1997, Thrombosis research.

Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates.

D. Hoppensteadt, J. Fareed, John M. Lee, 2003, Thrombosis research.

Laboratory monitoring of pentasaccharide in a dog model of hemodialysis.

T. Ing, J. Herbert, D. Hoppensteadt, 1999, Thrombosis research.

Sustained Release of Tissue Factor Following Thrombosis of Lower Limb Trauma

D. Hoppensteadt, J. Fareed, W. Jeske, 2014, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Effect of SR121566A, a Potent GP IIb-IIIa Antagonist, on the HIT Serum/heparin-Induced Platelet Mediated Activation of Human Endothelial Cells

J. Herbert, P. Savi, W. Jeske, 1998, Thrombosis and Haemostasis.

Apixaban as an Alternate Oral Anticoagulant for the Management of Patients With Heparin-Induced Thrombocytopenia

D. Hoppensteadt, W. Jeske, J. Walenga, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Protamine Sulfate Neutralization Profile of Various Dosages of Bovine, Ovine and Porcine UFHs and Their Depolymerized Derivatives in Non-Human Primates

D. Hoppensteadt, J. Fareed, W. Jeske, 2021, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa

Joseph Lewis, J. Fareed, O. Iqbal, 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Anticoagulant Effects of a Synthetic Anti-Factor Xa Inhibitor ( DX-9065 a ) : Implications for Interventional Use

D. Hoppensteadt, J. Fareed, Q. Ma, 2006 .

Global Anticoagulant Effects of a Synthetic Anti-Factor Xa Inhibitor (DX-9065a): Implications for Interventional Use

D. Hoppensteadt, J. Fareed, Q. Ma, 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

In vitro studies on the effect of activated protein C on platelet activation and thrombin generation.

J. Fareed, D. Hoppensteadt, W. Jeske, 1997, Thrombosis research.

Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction.

D. Wilber, J. Akar, W. Jeske, 2008, Journal of the American College of Cardiology.

Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3.

R. Linhardt, B. Dudas, A. Daud, 2002, Thrombosis research.

Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide.

D. Hoppensteadt, J. Fareed, O. Iqbal, 1993, Seminars in thrombosis and hemostasis.

Comparative Studies on the Topical Administration of Mucopolysaccharide and Heparin Ointments in Nonhuman Primates

D. Hoppensteadt, J. Fareed, W. Jeske, 2010, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis?

Deepak L. Bhatt, T. Grosser, U. Marathi, 2017, Journal of the American College of Cardiology.

Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.

W. Jeske, J. Walenga, 2004, Methods in molecular medicine.

Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia

H. Messmore, W. Jeske, J. Walenga, 2003, Drug safety.

Heparin-Induced Thrombocytopenic Potential of GAG and Non-GAG-Based Antithrombotic Agents

W. Jeske, J. Walenga, S. Haas, 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Heparin-induced Thrombocytopenia: Clinical Considerations of Alternative Anticoagulation with Various Glycosaminoglycans and Thrombin Inhibitors

J. Fareed, W. Jeske, J. Walenga, 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Low molecular weight heparins: a developmental perspective.

D. Hoppensteadt, J. Fareed, W. Jeske, 1997, Expert opinion on investigational drugs.

Phase I--study with aprosulate, a new synthetic anticoagulant.

D. Hoppensteadt, P. Wyld, W. Jeske, 1993, Thrombosis research.

Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates.

J. Fareed, O. Iqbal, W. Jeske, 2000, Thrombosis research.

Functional Heterogeneity of Antiheparin-Platelet Factor 4 Antibodies: Implications in the Pathogenesis of the HIT Syndrome

J. Fareed, W. Jeske, J. Walenga, 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Biological Activities and Effects on the Platelet Aggregation of a Structurally Defined Curdlan Sulfate

D. Hoppensteadt, J. Fareed, W. Jeske, 1996 .

Acquired Defects of Fibrinolysis Associated with Thrombosis

D. Hoppensteadt, J. Fareed, W. Jeske, 1999, Seminars in thrombosis and hemostasis.

Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation.

D. Hoppensteadt, J. Fareed, H. Messmore, 1999, Seminars in thrombosis and hemostasis.

Laboratory tests for the diagnosis of heparin-induced thrombocytopenia.

W. Jeske, J. Walenga, M. Bakhos, 1999, Seminars in thrombosis and hemostasis.

The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low‐molecular‐weight heparin

D. Hoppensteadt, J. Fareed, W. Jeske, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

The Multistage Antimalarial Compound Calxinin Perturbates P. falciparum Ca2+ Homeostasis by Targeting a Unique Ion Channel

B. Ogutu, M. Kashif, B. Rathi, 2022, Pharmaceutics.

Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin

D. Hoppensteadt, J. Fareed, W. Jeske, 2014, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Modulation of Platelet Function by Recombinant Thrombomodulin Hematologic Implications

D. Hoppensteadt, J. Fareed, C. Adiguzel, 2007 .

The Available Low Molecular Weight Heparin Preparations Are Not the Same

J. Fareed, W. Jeske, J. Walenga, 1997 .

Are the available low-molecular-weight heparin preparations the same?

D. Hoppensteadt, J. Fareed, W. Jeske, 1996, Seminars in thrombosis and hemostasis.

Isolation and Characterization of Contaminants in Recalled Unfractionated Heparin and Low-Molecular-Weight Heparin

P. Hubert, D. Hoppensteadt, J. Fareed, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin

R. Linhardt, J. Cunanan, D. Hoppensteadt, 2008 .

Upregulation of Microparticles in DIC and its Impact on Inflammatory Processes

I. Thethi, J. Cunanan, D. Hoppensteadt, 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis.

P. Gorin, H. Nader, J. Fareed, 1999, Biochimica et biophysica acta.

Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism

J. Fareed, C. Adiguzel, O. Iqbal, 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia.

K. F. Izban, D. Hoppensteadt, J. Fareed, 1999, Seminars in thrombosis and hemostasis.

Analysis of 3-O-Sulfated Heparan Sulfate Using Isotopically Labeled Oligosaccharide Calibrants.

M. Gearing, K. Arnold, Yongmei Xu, 2022, Analytical chemistry.

A comparative study on the mechanism of the anticoagulant action of mollusc and mammalian heparins.

H. Nader, J. Fareed, E. Santos, 1995, Comparative biochemistry and physiology. Part A, Physiology.

Pharmacology of Synthetic and Biotechnology-Derived Homologues and Analogues of Heparin

J. Fareed, W. Jeske, 1995 .

Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates

D. Hoppensteadt, J. Fareed, W. Jeske, 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.

J. Fareed, W. Jeske, Jawed Fareed, 1993, Seminars in thrombosis and hemostasis.

Anticoagulant and antithrombotic actions of a semisynthetic beta-1,3-glucan sulfate.

J. Fareed, W. Jeske, S. Alban, 1995, Thrombosis research.

Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide.

Richard Kijowski, J. Fareed, D. Hoppensteadt, 1994, Thrombosis research.

Molecular weight profiling of low molecular weight heparins utilizing a heparinase degraded oligosaccharide mixture as a calibrator.

J. Fareed, W. Jeske, A. Ahsan, 1993, Thrombosis research.

Generic low-molecular-weight heparins: some practical considerations.

D. Hoppensteadt, J. Fareed, W. Jeske, 2004, Seminars in thrombosis and hemostasis.

IN FOCUS: Activation of platelets by heparin‐induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin

H. Messmore, W. Jeske, M. Prechel, 2005, Journal of thrombosis and haemostasis : JTH.

Simple Scoring System for Early Management of Heparin-Induced Thrombocytopenia

I. Thethi, H. Messmore, W. Jeske, 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test

W. Jeske, J. Walenga, M. Bakhos, 2001, Perfusion.

Pharmacologic Studies on Synthetic Analogues of Heparin with Selective Affinity to Endogenous Serine Protease Inhibitors

W. Jeske, 1996 .

Factor Xa inhibitors

D. Hoppensteadt, J. Fareed, W. Jeske, 2004, Methods in Molecular Medicine.

Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations

J. Fareed, D. Hoppensteadt, W. Jeske, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Pharmacological Profiling of Recombinant Tissue Factor Pathway Inhibitor

D. Hoppensteadt, J. Fareed, W. Jeske, 1996, Seminars in thrombosis and hemostasis.

Antiplatelet agents: current drugs and future trends.

J. F. Moran, H. Messmore, W. Jeske, 2005, Hematology/oncology clinics of North America.

Product Individuality of Commercially Available Low-Molecular-Weight Heparins and Their Generic Versions: Therapeutic Implications

D. Hoppensteadt, J. Fareed, W. Jeske, 2006, Clinical and applied thrombosis/hemostasis.

Biochemical and pharmacologic profile of defined molecular weight fractions of heparin.

D. Hoppensteadt, J. Fareed, W. Jeske, 1993, Seminars in thrombosis and hemostasis.

An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations

Meharvan Singh, C. Carter, F. Lievano, 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Meharvan Singh, C. Carter, F. Lievano, 2021, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Effects of Quetiapine on Platelets in Major Depression

J. Piletz, A. Halaris, W. Jeske, 2016 .

Factor Xa inhibitors: today and beyond.

D. Hoppensteadt, J. Fareed, W. Jeske, 2003, Current opinion in investigational drugs.

Isoamyl Nitrite Depolymerized Heparin as a Universal Calibrator for Heparins and Low Molecular Weight Heparins

J. Fareed, W. Jeske, H. Wolf, 2000, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.

D. Hoppensteadt, J. Fareed, W. Jeske, 1995, Thrombosis research.

Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin.

D. Hoppensteadt, J. Fareed, O. Iqbal, 1995, Seminars in thrombosis and hemostasis.

Molecular profiling and weight determination of heparins and depolymerized heparins.

J. Fareed, D. Hoppensteadt, J. Lormeau, 1995, Journal of pharmaceutical sciences.

Low-molecular-weight heparins: pharmacologic profile and product differentiation.

D. Hoppensteadt, J. Fareed, W. Jeske, 1998, The American journal of cardiology.

Modulation of Endothelium by Heparin and Related Polyelectrolytes

D. Hoppensteadt, J. Fareed, W. Jeske, 1996 .

Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.

M. Iacobelli, J. Cunanan, D. Hoppensteadt, 2009 .

Comparative Tissue Factor Pathway Inhibitor Release Potential of Heparins

D. Hoppensteadt, J. Fareed, Q. Ma, 2005, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Diff erences in pharmacokinetic behaviour of branded enoxaparin and a US generic version in a non-human primate model

Phd, J. Cunanan, D. Hoppensteadt, 2015 .

An Update on Low‐Molecular‐Weight Heparins

J. Fareed, W. Jeske, D. Hoppensteadt, 2014 .

Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels

M. Samama, D. Hoppensteadt, J. Fareed, 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Inhibitory effects of TFPI variants on thrombin and factor Xa generation in fibrinogen-deficient human plasma.

J. Fareed, D. Hoppensteadt, W. Jeske, 1994, Thrombosis research.

Heparin oligosaccharides as potential therapeutic agents in senile dementia.

R. Linhardt, J. Fareed, John M. Lee, 2007, Current pharmaceutical design.

Small-molecule direct antithrombins: argatroban.

J. Fareed, W. Jeske, 2004, Best practice & research. Clinical haematology.

Pharmacology of argatroban.

J. Fareed, W. Jeske, J. Walenga, 1999, Expert opinion on investigational drugs.

A Comparison of the Pharmacodynamic Behavior of Branded and Biosimilar Enoxaparin in Primates

D. Hoppensteadt, J. Fareed, E. Litinas, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin.

A. Bayol, J. Cunanan, J. Fareed, 2011, Thrombosis research.

In Vivo Neutralization of Unfractionated Heparin and Low-Molecular-Weight Heparin by a Novel Salicylamide Derivative

D. Hoppensteadt, J. Fareed, E. Litinas, 2010, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Structural and Functional Characterization of Low-molecular-weight Heparins: Impact on the Development of Guidelines for Generic Products

D. Hoppensteadt, J. Fareed, V. Bansal, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Differentiating Low-Molecular-Weight Heparins Based on Chemical, Biological, and Pharmacologic Properties: Implications for the Development of Generic Versions of Low-Molecular-Weight Heparins

D. Hoppensteadt, J. Fareed, C. Adiguzel, 2008, Seminars in Thrombosis and Hemostasis.

Development of generic low molecular weight heparins: a perspective.

D. Hoppensteadt, J. Fareed, W. Jeske, 2005, Hematology/oncology clinics of North America.

Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model.

J. Fareed, O. Iqbal, W. Jeske, 1996, Thrombosis research.

Factor Xa Inhibitors in the Control of Thrombogenesis

D. Hoppensteadt, J. Fareed, W. Jeske, 1999 .

Absolute pharmacokinetics of heparin in primates.

Fuming Zhang, Ke Xia, Yuefan Song, 2023, Carbohydrate polymers.

Resourcing of Heparin and Low Molecular Weight Heparins from Bovine, Ovine, and Porcine Origin. Studies to Demonstrate the Biosimilarities

J. Fareed, W. Jeske, J. Walenga, 2015 .

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study

Deepak L. Bhatt, U. Marathi, D. Angiolillo, 2019, Journal of Thrombosis and Thrombolysis.

Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins

D. Hoppensteadt, J. Fareed, O. Iqbal, 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin

R. Linhardt, Fuming Zhang, Shiguo Chen, 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin

D. Hoppensteadt, J. Fareed, W. Jeske, 2013, Drug, healthcare and patient safety.

Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels

D. Hoppensteadt, J. Fareed, O. Iqbal, 2019, Front. Med..

Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin).

D. Hoppensteadt, J. Fareed, W. Jeske, 1993, Seminars in thrombosis and hemostasis.

Hemodialysis Mediated Upregulation of Myeloperoxidase in End Stage Renal Disease: Pathophysiologic Implications

J. Cunanan, D. Hoppensteadt, J. Fareed, 2007 .

In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.

J. Fareed, W. Jeske, 1999, Seminars in thrombosis and hemostasis.

The association between AB blood group and neonatal disease.

W. Jeske, O. Habeeb, J. Muraskas, 2019, Journal of neonatal-perinatal medicine.

Advances in Heparins and Related Research. An Epilogue

J. Fareed, W. Jeske, P. Bacher, 2018, Molecules.

Metabolic differences of current thienopyridine antiplatelet agents

I. Thethi, J. Fareed, W. Jeske, 2013, Expert opinion on drug metabolism & toxicology.

Newer insights on the mechanism of heparin-induced thrombocytopenia.

W. Jeske, J. Walenga, M. Bakhos, 2004, Seminars in thrombosis and hemostasis.

Inflammatory and Hemostatic Activation in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting

B. Untch, W. Jeske, J. Walenga, 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin

J. Fareed, O. Iqbal, W. Jeske, 2023, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications.

W. Jeske, J. Walenga, S. Haas, 1999, Seminars in thrombosis and hemostasis.

Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study

N. Uriel, D. Farrar, J. Katz, 2022, ASAIO journal.

A consensus conference on complex biologics and low molecular weight heparins.

L. Ried, C. Carter, D. Hoppensteadt, 2010, International Angiology.

Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.

J. Fareed, W. Jeske, J. Walenga, 1999, Seminars in thrombosis and hemostasis.

Laboratory tests for heparin-induced thrombocytopenia: a multicenter study.

W. Jeske, J. Walenga, M. Bakhos, 1999, Seminars in hematology.

Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.

M. Samama, J. Fareed, W. Jeske, 2002, Turkish journal of haematology : official journal of Turkish Society of Haematology.

Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction.

S. Sadayappan, D. Hoppensteadt, J. Fareed, 2013, American journal of cardiovascular disease.

Modulatory Effects of Escherichia coli Capsular–Derived Sulfaminoheparosans and Heparins on Tissue Factor–Mediated Activation of Platelets: Flow Cytometric Analysis

D. Hoppensteadt, J. Fareed, W. Jeske, 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.

D. Hoppensteadt, J. Fareed, W. Jeske, 1994, Thrombosis research.

Development of a Synthetic Heparin Pentasaccharide as an Antithrombotic Drug

M. Samama, J. Fareed, W. Jeske, 2002 .

Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.

J. Cunanan, D. Hoppensteadt, J. Fareed, 2008, International Angiology.

Early outcomes of Basiliximab administration before and after lung allograft reperfusion

W. Vigneswaran, W. Jeske, M. Bakhos, 2019, Trends in Transplantation.

Simultaneous Monitoring of Argatroban and Its Major Metabolite Using an HPLC Method: Potential Clinical Applications

J. Fareed, O. Iqbal, W. Jeske, 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Pharmacological profile of reviparin-sodium.

D. Hoppensteadt, J. Fareed, W. Jeske, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Combined Thrombin and Platelet Inhibition Treatment for HIT Patients

J. Fareed, W. Jeske, J. Walenga, 1999 .

Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device

D. Hoppensteadt, W. Jeske, J. Walenga, 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Assay Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization Profiles of Generic Copies of Enoxaparin.

D. Hoppensteadt, J. Fareed, W. Jeske, 2006 .

Effect of 1,6-Anhydro Bicyclic Ring Structure on the Pharmacokinetic and Pharmacodynamic Behavior of Low Molecular Weight Heparin.

J. Fareed, Q. Ma, W. Jeske, 2004 .

Mechanism of blood coagulation. Newer aspects of anticoagulant and antithrombotic therapy

D. Hoppensteadt, J. Fareed, W. Jeske, 2000 .

Multiplex genome editing of mammalian cells for producing recombinant heparin.

Benjamin P. Kellman, C. Glass, N. Lewis, 2022, Metabolic engineering.

Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.

Jason E. Moore, Deepak L. Bhatt, T. Grosser, 2017, Journal of the American College of Cardiology.

A Comparison of the Pharmacodynamic Behavior of Branded and Biosimilar Enoxaparin in Primates

D. Hoppensteadt, J. Fareed, E. Litinas, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis

D. Hoppensteadt, J. Fareed, O. Iqbal, 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Biochemical and Pharmacologic Characteristics of Reviparin, a Low-Molecular-Mass Heparin

J. Fareed, D. Hoppensteadt, O. Iqbal, 1997, Seminars in thrombosis and hemostasis.

The Approach of Thromboelastography in the Monitoring of New Synthetic Antithrombotic Agents, GL-522 and GL-2021

J. Fareed, O. Iqbal, W. Jeske, 1995, Seminars in Thrombosis & Hemostasis.

Antithrombotic agents stimulate the synthesis and modify the sulfation pattern of a heparan sulfate proteoglycan from endothelial cells.

H. Nader, D. Hoppensteadt, J. Fareed, 1994, Thrombosis research.

Generic Low Molecular Weight Heparins : Where Do We Stand ?

A. Sasahara, D. Hoppensteadt, J. Fareed, 2007 .

Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.

D. Hoppensteadt, J. Fareed, W. Jeske, 2012, International angiology : a journal of the International Union of Angiology.

From the Midwestern Vascular Surgical Society Synthetic , organic compound vepoloxamer ( P-188 ) potentiates tissue plasminogen activator

D. Hoppensteadt, J. Fareed, Jae-Sung Cho, 2016 .

Pharmacologic Profile of a Low-Molecular-Weight Heparin Depolymerized by γ-Irradiation

J. Fareed, G. Torri, W. Jeske, 1995 .

Antithrombin III Affinity Dependence on the Anticoagulant, Antiprotease, and Tissue Factor Pathway Inhibitor Actions of Heparins

D. Hoppensteadt, J. Lormeau, O. Iqbal, 1995, Seminars in thrombosis and hemostasis.